BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.

Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” fourth quarter 2024 investor letter. A copy ...

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that ...

Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...

Below is Validea's guru fundamental report for BECTON DICKINSON AND CO (BDX). Of the 22 guru strategies we follow, BDX rates highest using our P/E/Growth Investor model based on the published ...

BDx Data Centers, the largest data centre operator in Indonesia, is aiming to open a dozen data centres in the Southeast Asian nation with a target of 250 megawatts of capacity within the next two ...

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...

Becton Dickinson plans to invest more than $30M in 2025 to expand its manufacturing capacity for IV lines at its Utah plant.